摘要
目的:考察健康人体内达稳态时普卢利沙星对多索茶碱药动学的影响。方法:采用高效液相色谱法测定男性健康受试者给药前、后不同时间点多索茶碱的血药浓度。药-时数据用非线性程序WINNONLIN拟合,求得药动学参数。结果:多索茶碱在健康人体内呈一级吸收一室开放模型;合用前、后测得多索茶碱的主要药动学参数分别为:cmax(10.280±3.234)、(10.958±3.934)mg/L,t1/2a(0.218±0.179)、(0.298±0.182)h,tmax(0.883±0.458)、(1.222±0.475)h,t1/2β(4.770±3.311)、(5.537±3.577)h,AUC0-12hss(90.934±88.380)、(121.774±108.162)mg·h/L。结论:在该给药剂量下,两药合用在药动学上无明显的相互作用,提示两药临床上可以合用,但应注意监测多索茶碱的血药浓度。
OBJECTIVE: To study the effect of prulifloxacin on pharmacokinetics of doxofylline in healthy volunteers. METHODS: The blood concentration of doxofylline in male healthy volunteers were measured by HPLC at different time points before and after medication. The plasma concentration-time data were accessed by non-linear program (WINNONL IN) and the pharmaco- kinetic parameters were obtained. RESULTS: The blood concentration-time curve of doxofylline was adequately fitted as one order adsorption one-compartment open model. Main pharmacokinetic parameters of doxofylline alone vs. combined with prulifloxacin were as follows: Cm (10.280 ± 3.234)mg/L vs.(10.958 ± 3.934)mg/L;t2a(0.218 ± 0.179)h vs. (0.298 ± 0.182)h;tm(0.883 ± 0.458) h vs.(1.222 ± 0.475)h;l,jz(4.770 ± 3.311)h vs.(5.537 ± 3.577)h;AUC-12h(90.934 ± 88.380)mg.h/L vs. (121.774 ± 108.162)mg.h/L. CONCLUSIONS: There is no obvious interaction of pharmacokinetics when doxofylline and prulifloxacin are co-administered. They can be taken simultaneously, but the blood concentration of doxofylline should be monitored.
出处
《中国药房》
CAS
CSCD
2013年第18期1668-1670,共3页
China Pharmacy